![](/img/cover-not-exists.png)
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
Papp, K., Thaçi, D., Reich, K., Riedl, E., Langley, R.G., Krueger, J.G., Gottlieb, A.B., Nakagawa, H., Bowman, E.P., Mehta, A., Li, Q., Zhou, Y., Shames, R.Volume:
173
Language:
english
Journal:
British Journal of Dermatology
DOI:
10.1111/bjd.13932
Date:
October, 2015
File:
PDF, 343 KB
english, 2015